VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)

Currently, three ADCs have received Food and Drug Administration (FDA) approval for use in gynecologic malignancies: mirvetuximab soravtansine, tisotumab vedotin, and trastuzumab deruxtecan. Furthermore, the inherent complexities of these drugs and their mechanisms of action underscore the need for further research into the relevance of biomarkers, methods of therapy resistance, and the potential for re-utilization of payloads and targets later in the disease course. This review focuses on the mechanisms of action of ADCs, their developmental trajectory, successes in gynecologic cancers, emerging areas of investigation, the prospective landscape, and current challenges in the field.

Major challenges include heterogeneity and temporal variability of TAA expression, cytokine release syndrome (CRS) mitigation strategies, pharmacodynamic optimization, and delivery methods to maximize tumor bioavailability while limiting systemic toxicity. This review details the molecular mechanisms, preclinical evidence, clinical trial outcomes, and translational challenges for BsAbs in breast cancer, highlighting their transformative potential in expanding immunotherapeutic efficacy beyond current limitations.

In contrast, there was a discrepancy in AQP5 expression at the protein level compared to its gene counterpart. While this approach was valuable in identifying novel targets for tumor targeted imaging of EOC, immunohistochemistry or cell studies remain imperative for validation of RNA expression results.

Our study identifies a novel mechanism by which a fully human anti-B7-H4 antibody induces lysosome-dependent immunogenic tumor cell death. These findings support the therapeutic potential of A8 as a single agent or in combination with PD-1 blockade to overcome immune resistance in B7-H4-expressing "cold" tumors.

The multivariate analysis showed IS to be an independent prognostic biomarker for OS (hazard ratio: 2.212, 95% confidence interval: 1.597-3.063, P<0.001). This study identified different expression patterns of six immune checkpoints in GC, and IS based on the expression of four markers, could serve independently as a predictor of OS in GC, which might provide potential immune targets for GC patients.

We validated MAPK10 promoter hypermethylation and CCL18 overexpression as prognostic biomarkers in ABC DLBCL. These findings, derived from integrative transcriptomic and immunogenomic profiling, provide clinically relevant insights into disease biology and support biomarker-guided strategies for precision treatment in aggressive B-cell lymphomas.

Correlations between targets can help guide design of bispecific ADCs. Taken together, the results of this study can help inform the design and prioritization of drugs for the treatment of patients with metastatic breast cancer.

Preclinical models and early-phase clinical studies demonstrate encouraging antitumor activity, including in treatment-resistant disease. By integrating advances in tumor immunobiology and ADC technology, this review explores how targeting B7-H3 and B7-H4 could reshape therapeutic strategies in ovarian cancer.

The humanized anti-TM4SF4 antibody, Hz2B7-1.2, exhibits strong antitumor activity through multiple mechanisms, including inhibition of oncogenic signaling pathways, reduction of EMT-associated stemness, and modulation of immune responses. These findings support Hz2B7-1.2 as a promising therapeutic candidate for TM4SF4-positive cancers, warranting further clinical investigation.

In conclusion, we conducted a thorough analysis of the expression profiles of OSRGs in ccRCC, culminating in the development of a robust prognostic model and scoring system aimed at accurately predicting survival outcomes for ccRCC patients. This endeavor has the potential to yield novel insights into redox biology and to advance the current treatment strategies for ccRCC.

Notably, CD276, PD-L1, and B7H4 exhibited dominant expression on EV surfaces, with marked alterations in their levels following EGFR inhibitor treatment, highlighting the dynamic nature of immune modulation in response to therapy. These findings underscore the clinical utility of the mesoporous Au-integrated SERS platform for non-invasive lung cancer diagnostics and longitudinal monitoring of immunotherapy-induced immune modulation.

The CD2 receptor is an attractive costimulation target owing to its association with T cell receptor signaling and favorable expression profile...We demonstrate that ULBP2-targeted trispecifics with integrated CD2 costimulation and optimized CD3 affinity are superior to higher-affinity CD3 molecules in in vivo mouse efficacy studies. This integrated CD2 costimulation platform, which we termed EVOLVE, represents a next-generation TCE platform to increase T cell effector function in the tumor microenvironment and has the potential to address unmet patient needs by improving the depth and durability of clinical antitumor T cell responses.